The digital health space has expanded significantly in recent years, particularly during the Covid-19 pandemic.
The US Food and Drug Administration (FDA) observed an increase in the development and adoption of digital health advancements in 2020.
Go deeper with GlobalData
The introduction of AI-powered diagnostic tools highlights the industry’s shift to precision medicine approaches.
These tools enable a personalised approach to healthcare by using advanced algorithms to analyse biological and clinical data, taking into account individual patient characteristics, biomarkers, and disease profiles.
Precision medicine reflects a broader trend of tailoring therapeutic interventions to improve treatment efficacy and patient safety.
Integrating AI-powered digital health solutions with existing healthcare systems such as electronic medical records (EMRs) allows clinicians to have seamless access to diagnostic insights and patient data.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe FDA’s recent authorisation of the Sepsis ImmunoScore by Prenosis, the first AI diagnostic approved tool for sepsis, demonstrates that AI has a transformative potential to improve patient safety in hospitals and healthcare facilities.
The AI/machine learning software, which is directly integrated into hospital EMRs, improves clinical workflow efficiency, collaborative decision-making, and patient safety by providing real-time diagnostic information at the point of care.
This integration demonstrates the growing emphasis on interoperability and data-driven healthcare delivery models.
Sepsis is a life-threatening condition that requires immediate attention for successful treatment.
Traditional diagnostic methods for sepsis frequently rely on clinical judgment, which can cause delays in diagnosis and treatment.
This AI-driven diagnostic tool uses advanced algorithms to analyse biomarkers and clinical data, allowing for rapid and accurate identification of sepsis risk.
Early detection enabled by AI can lead to timely interventions, reducing complications and improving patient outcomes.
In addition, AI can help predict patient outcomes and determine the risk of disease progression.
The software as a medical device assigns patients to risk groups based on their sepsis risk score, giving clinicians valuable information about the likelihood of deterioration, length of hospital stay, and the need for escalated care such as intensive care unit admission or mechanical ventilation.
Identifying high-risk patients early on allows healthcare providers to better allocate resources and tailor interventions to individual patient needs, ultimately reducing adverse outcomes and improving patient safety.
In summary, AI has enormous potential for improving patient safety in hospitals and healthcare facilities by enabling early detection and diagnosis, risk assessment and prediction, seamless integration with existing healthcare systems, and the development of personalised therapeutic interventions.
The FDA’s approval of AI diagnostic tools such as the Sepsis ImmunoScore marks a significant step towards realising AI’s potential to improve patient care and outcomes in acute care settings.
